Closed-Path Microfluidic Processing for Sterile Polynucleotide Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for manufacturing and formulating polynucleotide therapeutics, particularly mRNA therapeutics, are prone to contamination and degradation, and centralized production is costly and slow, lacking scalability and point-of-care capabilities.
Innovation Solution
The development of microfluidic apparatuses and devices that operate in a closed path, utilizing a seating mount, fluid vials, fluidic lines, and a controller to drive fluidic movement, enabling in vitro transcription and purification of therapeutic polynucleotides, with features like optical sensors and thermal control to ensure sterility and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If centralized production is used for manufacturing polynucleotide therapeutics, then production capacity is increased, but cost increases and contamination risk increases
Solution Approach 1:
The system segments the manufacturing process into multiple independent microfluidic channels and reaction chambers, allowing parallel processing of multiple therapeutic samples simultaneously. Each channel operates as an isolated unit, enabling centralized production capacity while maintaining individual contamination barriers through the microfluidic architecture.
Solution Approach 2:
The microfluidic system creates a closed, controlled environment for each reaction channel that is isolated from the external environment. The sealed microfluidic pathways and controlled atmosphere within each channel prevent contamination while enabling parallel processing, thus resolving the contradiction between production capacity and contamination risk.
2Productivity
If centralized production is used for manufacturing polynucleotide therapeutics, then production capacity is increased, but manufacturing time increases
Solution Approach 1:
The manufacturing process is divided into multiple parallel microfluidic channels that can operate simultaneously. This segmentation allows multiple therapeutic productions to occur in parallel rather than sequentially, dramatically reducing total manufacturing time while maintaining high production capacity through the centralized system.
Solution Approach 2:
The microfluidic system enables continuous flow and real-time processing through automated fluid delivery and thermal cycling. Reagents are continuously supplied through pumped flows, and reactions proceed through automated temperature cycles, eliminating idle time and accelerating the manufacturing process while maintaining high throughput.
3Device complexity
If conventional manufacturing methods are used, then process simplicity is maintained, but manufacturing precision and sterility control deteriorate
Solution Approach 1:
Each microfluidic channel operates as a sealed, controlled environment that is physically isolated from the external environment. The closed microfluidic pathways maintain sterility through physical barriers while the automated system manages complexity, achieving both precision sterility control and manageable operational simplicity.
Solution Approach 2:
The system incorporates automated fluid delivery, thermal cycling, and monitoring that self-regulate the manufacturing process. The microfluidic apparatus automatically controls reagent addition, temperature, and flow rates without requiring manual intervention, thereby achieving high manufacturing precision while simplifying the operational process through automation.
4Productivity
If scalable manufacturing is implemented, then production capacity increases, but contamination risk increases
Solution Approach 1:
The scalable architecture uses multiple identical microfluidic channels that can be replicated and operated in parallel. Each channel remains an isolated containment unit, so scaling the number of channels increases production capacity while the physical separation in each channel maintains contamination barriers, enabling scalable manufacturing without proportionally increasing contamination risk.
Data Source
AI summary
Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.